Plasmalogen restoration therapy

July 15, 2016

Dr. Dayan Goodenowe describes plasmalogen restoration therapy for the treatment of the rare genetic children’s disease rhizomelic chondrodysplasia punctata at the annual RCDP Conference

On July 14, 2016, Dr. Dayan Goodenowe, founder of Prodrome Sciences Inc., presented the potential utility of using therapeutic plasmalogen restoration for the treatment of a rare genetic disease in children called rhizomelic chondrodysplasia punctata (RCDP) at the annual RCDP conference in Alexander City, Alabama.

Children born with RCDP have rare genetic defects that prevent their body from making plasmalogen molecules. Children with RCDP have shortened limbs, intellectual disability, and breathing problems. Approximately half of the children die before their fifth birthday and nearly all of the children succumb to the disease by adolescence. There are no therapies to improve the disease and there is no cure. The severity of RCDP emphasizes how important plasmalogen molecules are to human health. Prodrome Sciences believes that restoring the levels of plasmalogen molecules in RCDP children to the same levels in healthy children will improve their quality of life and increase their life expectancy.

Plasmalogens are a type of lipid (fat) that your body uses to keep cellular membranes in good working order. They are especially important for neurons in your brain. When your membranes do not have enough of these lipid molecules, they become rigid and stop functioning properly. Dr. Goodenowe is the inventor of several patents relating to the role of plasmalogens in neurodegenerative diseases. 

Contact us for more information.

Keep in touch

©2020 Prodrome Sciences Inc.